Top

Published in:

01-12-2019 | Erectile Dysfunction | Female Sexual Dysfunction and Disorders (A Pastuszak and N Thirumavalavan, Section Editors)

Management of the Acute Phase of Peyronie’s Disease: a Contemporary Review

Authors: Dyvon T. Walker, Arash Amighi, Steven A. Mills, Sriram V. Eleswarapu, Jesse N. Mills

Published in: Current Sexual Health Reports | Issue 4/2019

Abstract

Purpose of Review

The goal of this article is to review the current management options for Peyronie’s disease (PD), focusing on the acute phase of the disease. Additionally, we aim to highlight the most recent literature on the subject.

Recent Findings

Contemporary studies suggest that there are promising novel therapies on the horizon for acute phase PD, such as topical H-100 gel and intralesional interferon-α2b and mycophenolate mofetil. Recent findings also suggest that intralesional collagenase Clostridium histolyticum (CCH) may be effective for the acute phase of PD, in addition to its conventional use in the chronic phase.

Summary

A variety of treatments have been proposed for PD, with more recent literature focusing on the acute phase. Novel topical therapies are on the horizon and may show promise. External mechanical therapies have shown clinically meaningful changes. CCH may have efficacy during the acute phase of PD. Other intralesional therapies are promising but still require additional large studies to confirm efficacy. Future research on the acute phase of PD may expand treatment options and impact disease management.

Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503. https://doi.org/10.1155/2011/282503.CrossRefPubMedPubMedCentral

Ostrowski KA, Gannon JR, Walsh TJ. A review of the epidemiology and treatment of Peyronie’s disease. Res Rep Urol. 2016;8:61–70. https://doi.org/10.2147/RRU.S65620.CrossRefPubMedPubMedCentral

Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med. 2008;5(8):1985–90. https://doi.org/10.1111/j.1743-6109.2008.00895.x.CrossRefPubMed

Smith JF, Walsh TJ, Conti SL, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie’s disease. J Sex Med. 2008;5(9):2179–84. https://doi.org/10.1111/j.1743-6109.2008.00949.x.CrossRefPubMedPubMedCentral

Levine LA. Peyronie’s disease: contemporary review of non-surgical treatment. Transl Androl Urol. 2013;2(1):39–44. https://doi.org/10.3978/j.issn.2223-4683.2013.01.01.CrossRefPubMedPubMedCentral

Chung E, Clendinning E, Lessard L, Brock G. Five-year follow-up of Peyronie’s graft surgery: outcomes and patient satisfaction. J Sex Med. 2011;8(2):594–600. https://doi.org/10.1111/j.1743-6109.2010.02102.x.CrossRefPubMed

Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194(3):745–53. https://doi.org/10.1016/j.juro.2015.05.098.CrossRefPubMedPubMedCentral

Tefekli A, Kandirali E, Erol H, Alp T, Koksal T, Kadioglu A. Peyronie’s disease in men under age 40: characteristics and outcome. Int J Impot Res. 2001;13(1):18–23. https://doi.org/10.1038/sj.ijir.3900635.CrossRefPubMed

Gelbard MK, Dorey F, James K. The natural history of Peyronie’s disease. J Urol. 1990;144(6):1376–9.CrossRef

10.

• Favilla V, Russo GI, Zucchi A, Siracusa G, Privitera S, Cimino S, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie’s disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017;5(4):771–5. https://doi.org/10.1111/andr.12368This prospective, double-blinded, randomized study described improvements in penile curvature and patient satisfaction with the use of intralesional HA, and is thus an important study in the evaluation of HA for PD therapy. CrossRefPubMed

11.

Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175(6):2115–8; discussion 8. https://doi.org/10.1016/S0022-5347(06)00270-9.CrossRefPubMed

12.

Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268–74. https://doi.org/10.1016/j.juro.2012.01.032.CrossRefPubMed

13.

Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207. https://doi.org/10.1016/j.juro.2013.01.087.CrossRefPubMed

14.

Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248–58. https://doi.org/10.1111/jsm.12731.CrossRefPubMed

15.

Zucchi A, Costantini E, Cai T, Cavallini G, Liguori G, Favilla V, et al. Intralesional injection of hyaluronic acid in patients affected with Peyronie’s disease: preliminary results from a prospective, multicenter, pilot study. Sex Med. 2016;4(2):e83–8. https://doi.org/10.1016/j.esxm.2016.01.002.CrossRefPubMed

16.

•• Twidwell J, Levine L. Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int J Impot Res. 2016;28(2):41–5. https://doi.org/10.1038/ijir.2015.22This randomized, prospective, placebo-controlled pilot study evaluated the use of a potentially novel topical therapy for PD, H-100 gel, with promising results. CrossRefPubMed

17.

•• Nguyen HMT, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJG. Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie’s disease. J Sex Med. 2017;14(10):1220–5. https://doi.org/10.1016/j.jsxm.2017.08.008This study suggests that CCH use during the acute phase can be effective and safe, an important result for future research and management guidelines. CrossRefPubMed

18.

Martinez-Salamanca JI, Egui A, Moncada I, Minaya J, Ballesteros CM, Del Portillo L, et al. Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11(2):506–15. https://doi.org/10.1111/jsm.12400.CrossRefPubMed

19.

• Randhawa K, Shukla CJ. Non-invasive treatment in the management of Peyronie’s disease. Ther Adv Urol. 2019;11:1756287218823671. https://doi.org/10.1177/1756287218823671This review article provides a recent overview of PD management options without focus on a particular phase of PD. CrossRefPubMedPubMedCentral

20.

Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229–44. https://doi.org/10.1016/j.niox.2003.12.002.CrossRefPubMed

21.

Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543–52. https://doi.org/10.1016/j.eururo.2012.05.040.CrossRefPubMed

22.

Levine LA, Latchamsetty KC. Treatment of erectile dysfunction in patients with Peyronie’s disease using sildenafil citrate. Int J Impot Res. 2002;14(6):478–82. https://doi.org/10.1038/sj.ijir.3900912.CrossRefPubMed

23.

• Tsambarlis P, Levine LA. Nonsurgical management of Peyronie’s disease. Nat Rev Urol. 2019;16(3):172–86. https://doi.org/10.1038/s41585-018-0117-7This review article provides a recent overview of PD management options without focus on a particular phase of PD. CrossRefPubMed

24.

Aggeler J, Frisch SM, Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. J Cell Biol. 1984;98(5):1662–71. https://doi.org/10.1083/jcb.98.5.1662.CrossRefPubMed

25.

Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. Evidence-based management guidelines on Peyronie’s disease. J Sex Med. 2016;13(6):905–23. https://doi.org/10.1016/j.jsxm.2016.04.062.CrossRefPubMed

26.

Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168(6):2483–5. https://doi.org/10.1097/01.ju.0000031440.26763.da.CrossRefPubMed

27.

Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003;169(5):1775–8. https://doi.org/10.1097/01.ju.0000056153.47716.d0.CrossRefPubMed

28.

Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol. 2007;177(3):972–5. https://doi.org/10.1016/j.juro.2006.10.065.CrossRefPubMed

29.

Mehrsai AR, Namdari F, Salavati A, Dehghani S, Allameh F, Pourmand G. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie’s disease. Andrology. 2013;1(1):129–32. https://doi.org/10.1111/j.2047-2927.2012.00018.x.CrossRefPubMed

30.

Montorsi F, Salonia A, Guazzoni G, Barbieri L, Colombo R, Brausi M, et al. Transdermal electromotive multi-drug administration for Peyronie’s disease: preliminary results. J Androl. 2000;21(1):85–90.PubMed

31.

Riedl CR, Plas E, Engelhardt P, Daha K, Pfluger H. Iontophoresis for treatment of Peyronie’s disease. J Urol. 2000;163(1):95–9.CrossRef

32.

• Amighi A, Mills SA, Eleswarapu SV, Regets KV, Mendhiratta N, Mills JN. A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie’s disease results in reduced procedural morbidity using a standardized hematoma classification rubric. World J Urol. 2019. https://doi.org/10.1007/s00345-019-02812-9This article proposes a modified technique for intralesional injection of CCH, showing reduced procedural morbidity.

33.

• Fernandez-Pascual E, Gonzalez-Garcia FJ, Angulo J, Cerezo E, Quintana LM, Turo J, et al. Optimizing collagenase Clostridium histolyticum therapy for Peyronie’s disease using a novel approach with percutaneous needle tunnelling. BJU Int. 2019. https://doi.org/10.1111/bju.14784This article describes a specific technique for intralesional injection of CCH with improved outcomes.

34.

Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R. Betamethasone versus placebo in Peyronie’s disease. Arch Ital Urol Androl. 1998;70(4):165–8.PubMed

35.

Desanctis PN, Furey CA Jr. Steroid injection therapy for Peyronie’s disease: a 10-year summary and review of 38 cases. J Urol. 1967;97(1):114–6. https://doi.org/10.1016/s0022-5347(17)62993-8.CrossRefPubMed

36.

Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet injection of dexamethasone. J Urol. 1975;114(6):898–900. https://doi.org/10.1016/s0022-5347(17)67169-6.CrossRefPubMed

37.

• Haney NM, Kohn TP, Nichols PE, Jg Hellstrom W. The effect of adjunct mechanical traction on penile length in men undergoing primary treatment for Peyronie’s disease: a systematic review and meta-analysis. Urology. 2018;122:110–5. https://doi.org/10.1016/j.urology.2018.07.039This meta-analysis explored the use of penile traction therapy in conjunction with PD treatment. As mechanical traction therapy is often used in conduction with CCH therapy in clinical practice, this article is important in evaluating the efficacy of such. CrossRefPubMed

38.

Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116(4):650–6. https://doi.org/10.1111/bju.13096.CrossRefPubMed

39.

Brazzelli M, Cruickshank M, Tassie E, McNamee P, Robertson C, Elders A, et al. Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation. Health Technol Assess. 2015;19(90):1–202. https://doi.org/10.3310/hta19900.CrossRefPubMedPubMedCentral

40.

Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol. 1993;149(1):56–8.CrossRef

41.

Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008;5(1):180–7. https://doi.org/10.1111/j.1743-6109.2007.00651.x.CrossRefPubMed

42.

• Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, et al. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int. 2017;120(5):717–23. https://doi.org/10.1111/bju.13932This prospective study evaluated a shortened protocol for the intralesional injection of CCH, showing the method to be both efficacious and cost efficient. When considering the potentially high cost of CCH therapy, it is important that this study demonstrated a more cost-efficient protocol. CrossRefPubMed

43.

Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie’s disease. J Urol. 2016;195(4 Pt 1):1051–6. https://doi.org/10.1016/j.juro.2015.10.065.CrossRefPubMed

44.

•• El-Khatib FM, Towe M, Yafi FA. Management of Peyronie’s disease with collagenase Clostridium histolyticum in the acute phase. World J Urol. 2019. https://doi.org/10.1007/s00345-019-02791-xThis review article summarized the use of intralesional injection of CCH in the acute phase of PD, concluding that there may be comparable efficacy as to treatment of chronic phase.

45.

Cordon BH, Hofer MD, Hutchinson RC, Broderick GA, Lotan Y, Morey AF. Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie’s disease deformities. Urol Pract. 2017;(4):118–25. https://doi.org/10.1016/j.urpr.2016.04.005.

46.

• Abdel Raheem A, Johnson M, Ralph D, Garaffa G. Collagenase clostridium histolyticum: a novel medical treatment for Peyronie’s disease. Minerva Urol Nefrol. 2018;70(4):380–5. https://doi.org/10.23736/S0393-2249.18.03118-1This article suggests a new modified protocol for the intralesional injection of CCH that reduces the cost and inconvenience to patients while maintaining efficacy. This will potentially allow more men to benefit and will reduce the number of men undergoing surgical correction for their PD. CrossRefPubMed

47.

Gabrielson AT, Spitz JT, Hellstrom WJG. Collagenase Clostridium histolyticum in the treatment of urologic disease: current and future impact. Sex Med Rev. 2018;6(1):143–56. https://doi.org/10.1016/j.sxmr.2017.03.005.CrossRefPubMed

48.

•• Alom M, Meng Y, Sharma KL, Savage J, Kohler T, Trost L. Safety and efficacy of collagenase Clostridium histolyticum in Peyronie’s disease men with ventral curvatures. Urology. 2019;129:119–25. https://doi.org/10.1016/j.urology.2019.01.055This prospective study explored the use of intralesional injection of CCH in ventral curvatures. This study is important as CCH has previously been studied widely for dorsal curvatures only. CrossRefPubMed

49.

Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A. 1996;93(11):5478–82. https://doi.org/10.1073/pnas.93.11.5478.CrossRefPubMedPubMedCentral

50.

Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie’s disease. Urology. 2007;69(6):1181–4. https://doi.org/10.1016/j.urology.2007.02.042.CrossRefPubMed

51.

Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol. 1997;158(4):1395–9.CrossRef

52.

Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168(2):621–5; discussion 5-6. https://doi.org/10.1016/s0022-5347(05)64691-5.CrossRefPubMed

53.

Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522–4. https://doi.org/10.1016/s0022-5347(17)35291-6.CrossRefPubMed

54.

Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620–6.CrossRef

55.

Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467–71. https://doi.org/10.1007/s11255-009-9522-4.CrossRefPubMed

56.

Dell’Atti L. Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie’s disease. Urol Ann. 2015;7(3):345–9. https://doi.org/10.4103/0974-7796.152048.CrossRefPubMedPubMedCentral

57.

Toscano L Jr, Rezende MV, Mello LF, Paulillo D, Glina S. A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie’s disease: a pilot study. Int Braz J Urol. 2016;42(5):1005–9. https://doi.org/10.1590/S1677-5538.IBJU.2015.0598.CrossRefPubMedPubMedCentral

58.

Gennaro R, Barletta D, Paulis G. Intralesional hyaluronic acid: an innovative treatment for Peyronie’s disease. Int Urol Nephrol. 2015;47(10):1595–602. https://doi.org/10.1007/s11255-015-1074-1.CrossRefPubMed

59.

Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Res Ther. 2014;16(1):204. https://doi.org/10.1186/ar4493.CrossRefPubMedPubMedCentral

60.

• Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol. 2018;59(1):61–5. https://doi.org/10.4111/icu.2018.59.1.61This article reports that the delivery of platelet-rich plasma via a platelet-rich fibrin matrix is safe and feasible for the treatment of ED, PD, and female SUI. This potentially opens doors for studies to evaluate efficacy of this therapy for PD. CrossRefPubMed

61.

Gigante A, Del Torto M, Manzotti S, Cianforlini M, Busilacchi A, Davidson PA, et al. Platelet rich fibrin matrix effects on skeletal muscle lesions: an experimental study. J Biol Regul Homeost Agents. 2012;26(3):475–84.PubMed

62.

Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med. 2008;1(3-4):165–74. https://doi.org/10.1007/s12178-008-9032-5.CrossRefPubMedPubMedCentral

63.

• Virag R, Sussman H, Lambion S, de Fourmestraux V. Evaluation of the benefit of using a combination of autologous platelet rich-plasma and hyaluronic acid for the treatment of Peyronie’s disease. Sex Health Issues. 2017;1:1–8. https://doi.org/10.15761/SHI.1000102This small study explored the use of a combination of PRP and HA in the treatment of PD with positive results, potentially leading to larger studies of this novel therapy. CrossRef

64.

Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25(2):89–94. https://doi.org/10.3109/00365599109024539.CrossRefPubMed

65.

Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie’s disease. Eur Urol. 2007;51(3):640–7. https://doi.org/10.1016/j.eururo.2006.10.042.CrossRefPubMed

66.

Wegner HE, Andresen R, Knipsel HH, Miller K. Treatment of Peyronie’s disease with local interferon-alpha 2b. Eur Urol. 1995;28(3):236–40.CrossRef

67.

Chong W, Tan RB. Injectable therapy for Peyronie’s disease. Transl Androl Urol. 2016;5(3):310–7. https://doi.org/10.21037/tau.2016.03.15.CrossRefPubMedPubMedCentral

68.

Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176(1):394–8. https://doi.org/10.1016/S0022-5347(06)00517-9.CrossRefPubMed

69.

• Russo GI, Cacciamani G, Cocci A, Kessler TM, Morgia G, Serefoglu EC, et al. Comparative effectiveness of intralesional therapy for Peyronie’s disease in controlled clinical studies: a systematic review and network meta-analysis. J Sex Med. 2019;16(2):289–99. https://doi.org/10.1016/j.jsxm.2018.12.011This systematic review and meta-analysis focuses on the current intralesional therapies for PD, providing evidence of the efficacy between different intralesional therapies. CrossRefPubMed

70.

Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther. 2007;321(2):583–9. https://doi.org/10.1124/jpet.106.117051.CrossRefPubMed

71.

•• Antoniassi T, Junior FNF, Spessoto LCF, Guerra LH, Campos SS, Taboga S. Anti-fibrotic effect of mycophenolate mofetil on Peyronie’s disease experimentally induced with TGF-beta. Int J Impot Res. 2019. https://doi.org/10.1038/s41443-019-0138-7This study evaluates the role of MMF in a murine PD model and suggests that the drug acts as a regenerating anti-fibrotic agent that may be useful for translation to human PD. This proposes a potential novel therapy for PD.

72.

Levine LA. Review of current nonsurgical management of Peyronie’s disease. Int J Impot Res. 2003;15(Suppl 5):S113–20. https://doi.org/10.1038/sj.ijir.3901084.CrossRefPubMed

73.

Hauck EW, Hauptmann A, Bschleipfer T, Schmelz HU, Altinkilic BM, Weidner W. Questionable efficacy of extracorporeal shock wave therapy for Peyronie’s disease: results of a prospective approach. J Urol. 2004;171(1):296–9. https://doi.org/10.1097/01.ju.0000099891.68488.4e.CrossRefPubMed

74.

Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol. 2009;56(2):363–9. https://doi.org/10.1016/j.eururo.2009.05.012.CrossRefPubMed

75.

Srirangam SJ, Manikandan R, Hussain J, Collins GN, O'Reilly PH. Long-term results of extracorporeal shockwave therapy for Peyronie’s disease. J Endourol. 2006;20(11):880–4. https://doi.org/10.1089/end.2006.20.880.CrossRefPubMed

76.

Strebel RT, Suter S, Sautter T, Hauri D. Extracorporeal shockwave therapy for Peyronie’s disease does not correct penile deformity. Int J Impot Res. 2004;16(5):448–51. https://doi.org/10.1038/sj.ijir.3901192.CrossRefPubMed

77.

Krieger JR, Rizk PJ, Kohn TP, Pastuszak A. Shockwave therapy in the treatment of Peyronie’s disease. Sex Med Rev. 2019. https://doi.org/10.1016/j.sxmr.2019.02.001.

78.

• di Mauro M, Russo GI, Della Camera PA, di Maida F, Cito G, Mondaini N, et al. Extracorporeal shock wave therapy in Peyronie’s disease: clinical efficacy and safety from a single-arm observational study. World J Mens Health. 2019. https://doi.org/10.5534/wjmh.180100As ESWT is currently not recommended for use for treatment of PD, this study showed positive, statistically significant results with the use of ESWT.

79.

Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106(8):1178–80. https://doi.org/10.1111/j.1464-410X.2010.09365.x.CrossRefPubMed

80.

Ralph DJ, Abdel Raheem A, Liu G. Treatment of Peyronie’s disease with collagenase Clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J Sex Med. 2017;14(11):1430–7. https://doi.org/10.1016/j.jsxm.2017.08.015.CrossRefPubMed

81.

Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost LW. Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease. Urology. 2017;104:102–9. https://doi.org/10.1016/j.urology.2017.01.054.CrossRefPubMed

82.

Yafi FA, Pinsky MR, Stewart C, Sangkum P, Ates E, Trost LW, et al. The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie’s disease. J Urol. 2015;194(3):754–8. https://doi.org/10.1016/j.juro.2015.03.092.CrossRefPubMed

83.

• Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase Clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie’s disease. J Sex Med. 2019;16(6):891–900. https://doi.org/10.1016/j.jsxm.2019.03.007This prospective study showed improved outcomes with the use of a traction therapy device in conjunction with CCH therapy. It provides evidence that a combination of therapies may be superior to monotherapy. CrossRefPubMed

84.

Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med. 2009;6(2):558–66. https://doi.org/10.1111/j.1743-6109.2008.01108.x.CrossRefPubMed

85.

Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468–73. https://doi.org/10.1111/j.1743-6109.2008.00814.x.CrossRefPubMed

86.

Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M. Surgical treatment of Peyronie’s disease: a critical analysis. Eur Urol. 2006;50(2):235–48. https://doi.org/10.1016/j.eururo.2006.04.030.CrossRefPubMed

87.

Savoca G, Scieri F, Pietropaolo F, Garaffa G, Belgrano E. Straightening corporoplasty for Peyronie’s disease: a review of 218 patients with median follow-up of 89 months. Eur Urol. 2004;46(5):610–4; discussion 3-4. https://doi.org/10.1016/j.eururo.2004.04.027.CrossRefPubMed

88.

Bokarica P, Parazajder J, Mazuran B, Gilja I. Surgical treatment of Peyronie’s disease based on penile length and degree of curvature. Int J Impot Res. 2005;17(2):170–4. https://doi.org/10.1038/sj.ijir.3901255.CrossRefPubMed

89.

Syed AH, Abbasi Z, Hargreave TB. Nesbit procedure for disabling Peyronie’s curvature: a median follow-up of 84 months. Urology. 2003;61(5):999–1003.CrossRef

90.

Ralph DJ. al-Akraa M, Pryor JP. The Nesbit operation for Peyronie’s disease: 16-year experience. J Urol. 1995;154(4):1362–3.CrossRef

91.

Licht MR, Lewis RW. Modified Nesbit procedure for the treatment of Peyronie’s disease: a comparative outcome analysis. J Urol. 1997;158(2):460–3.CrossRef

92.

Yachia D. Modified corporoplasty for the treatment of penile curvature. J Urol. 1990;143(1):80–2. https://doi.org/10.1016/s0022-5347(17)39871-3.CrossRefPubMed

93.

Daitch JA, Angermeier KW, Montague DK. Modified corporoplasty for penile curvature: long-term results and patient satisfaction. J Urol. 1999;162(6):2006–9. https://doi.org/10.1016/s0022-5347(05)68088-3.CrossRefPubMed

94.

Rehman J, Benet A, Minsky LS, Melman A. Results of surgical treatment for abnormal penile curvature: Peyronie’s disease and congenital deviation by modified Nesbit plication (tunical shaving and plication). J Urol. 1997;157(4):1288–91. https://doi.org/10.1016/s0022-5347(01)64953-x.CrossRefPubMed

95.

Mufti GR, Aitchison M, Bramwell SP, Paterson PJ, Scott R. Corporeal plication for surgical correction of Peyronie’s disease. J Urol. 1990;144(2 Pt 1):281–2; discussion 3. https://doi.org/10.1016/s0022-5347(17)39432-6.CrossRefPubMed

96.

Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol. 2002;167(5):2066–9.CrossRef

97.

Chahal R, Gogoi NK, Sundaram SK, Weston PM. Corporal plication for penile curvature caused by Peyronie’s disease: the patients’ perspective. BJU Int. 2001;87(4):352–6.CrossRef

98.

Geertsen UA, Brok KE, Andersen B, Nielsen HV. Peyronie curvature treated by plication of the penile fasciae. Br J Urol. 1996;77(5):733–5.CrossRef

99.

Thiounn N, Missirliu A, Zerbib M, Larrouy M, Dje K, Flam T, et al. Corporeal plication for surgical correction of penile curvature. Experience with 60 patients. Eur Urol. 1998;33(4):401–4.CrossRef

100.

Van Der Horst C, Martinez Portillo FJ, Seif C, Alken P, Juenemann KP. Treatment of penile curvature with Essed-Schroder tunical plication: aspects of quality of life from the patients’ perspective. BJU Int. 2004;93(1):105–8.CrossRef

101.

Schultheiss D, Meschi MR, Hagemann J, Truss MC, Stief CG, Jonas U. Congenital and acquired penile deviation treated with the essed plication method. Eur Urol. 2000;38(2):167–71. https://doi.org/10.1159/000020275.CrossRefPubMed

102.

Levine LA, Lenting EL. A surgical algorithm for the treatment of Peyronie’s disease. J Urol. 1997;158(6):2149–52. https://doi.org/10.1016/s0022-5347(01)68184-9.CrossRefPubMed

103.

Wild RM, Devine CJ Jr, Horton CE. Dermal graft repair of Peyronie’s disease: survey of 50 patients. J Urol. 1979;121(1):47–50. https://doi.org/10.1016/s0022-5347(17)56657-4.CrossRefPubMed

104.

Melman A, Holland TF. Evaluation of the dermal graft inlay technique for the surgical treatment of Peyronie’s disease. J Urol. 1978;120(4):421–2. https://doi.org/10.1016/s0022-5347(17)57209-2.CrossRefPubMed

105.

O'Donnell PD. Results of surgical management of Peyronie’s disease. J Urol. 1992;148(4):1184–7. https://doi.org/10.1016/s0022-5347(17)36854-4.CrossRefPubMed

106.

Das S. Peyronie’s disease: excision and autografting with tunica vaginalis. J Urol. 1980;124(6):818–9. https://doi.org/10.1016/s0022-5347(17)55682-7.CrossRefPubMed

107.

Kargi E, Yesilli C, Hosnuter M, Akduman B, Babuccu O, Mungan A. Relaxation incision and fascia lata grafting in the surgical correction of penile curvature in Peyronie’s disease. Plast Reconstr Surg. 2004;113(1):254–9. https://doi.org/10.1097/01.PRS.0000095951.04305.38.CrossRefPubMed

108.

Shioshvili TJ, Kakonashvili AP. The surgical treatment of Peyronie’s disease: replacement of plaque by free autograft of buccal mucosa. Eur Urol. 2005;48(1):129–33; discussion 34-5. https://doi.org/10.1016/j.eururo.2005.01.018.CrossRefPubMed

109.

Teloken C, Grazziotin T, Rhoden E, Da Ros C, Fornari A, Soares FC, et al. Penile straightening with crural graft of the corpus cavernosum. J Urol. 2000;164(1):107–8.CrossRef

110.

Kim ED, McVary KT. Long-term followup of treatment of Peyronie’s disease with plaque incision, carbon dioxide laser plaque ablation and placement of a deep dorsal vein patch graft. J Urol. 1995;153(6):1843–6.CrossRef

111.

Hsu YS, Huang WJ, Kuo JY, Chung HJ, Chen KK, Chang LS. Experience of surgical treatment of peyronie’s disease with deep dorsal venous patch graft in Taiwanese men. J Chin Med Assoc. 2003;66(8):487–91.PubMed

112.

Craatz S, Spanel-Borowski K, Begemann JF, Olianas R, Fisch M, Hohenfellner R. The dorsal lamina of the rectus sheath: a suitable grafting material for the penile tunica albuginea in Peyronie’s disease? BJU Int. 2006;97(1):134–7. https://doi.org/10.1111/j.1464-410X.2006.05876.x.CrossRefPubMed

113.

Gelbard MK, Hayden B. Expanding contractures of the tunica albuginea due to Peyronie’s disease with temporalis fascia free grafts. J Urol. 1991;145(4):772–6. https://doi.org/10.1016/s0022-5347(17)38447-1.CrossRefPubMed

114.

Kalsi J, Minhas S, Christopher N, Ralph D. The results of plaque incision and venous grafting (Lue procedure) to correct the penile deformity of Peyronie’s disease. BJU Int. 2005;95(7):1029–33. https://doi.org/10.1111/j.1464-410X.2005.05459.x.CrossRefPubMed

115.

De Stefani S, Savoca G, Ciampalini S, Gattuccio I, Scieri F, Belgrano E. Saphenous vein harvesting by ‘stripping’ technique and ‘W’-shaped patch covering after plaque incision in treatment of Peyronie’s disease. Int J Impot Res. 2000;12(6):299–301. https://doi.org/10.1038/sj.ijir.3900633.CrossRefPubMed

116.

Montorsi F, Salonia A, Maga T, Bua L, Guazzoni G, Barbieri L, et al. Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie’s disease. J Urol. 2000;163(6):1704–8.CrossRef

117.

Chen R, McCraw C, Lewis R. Plication procedures-excisional and incisional corporoplasty and imbrication for Peyronie’s disease. Transl Androl Urol. 2016;5(3):318–33. https://doi.org/10.21037/tau.2016.05.01.CrossRefPubMedPubMedCentral

118.

Carson CC. Penile prosthesis implantation in the treatment of Peyronie’s disease and erectile dysfunction. Int J Impot Res. 2000;12(Suppl 4):S122–6.CrossRef

119.

Levine LA, Dimitriou RJ. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie’s disease. Int J Impot Res. 2000;12(3):147–51.CrossRef

120.

Wilson SK, Delk JR 2nd. A new treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994;152(4):1121–3. https://doi.org/10.1016/s0022-5347(17)32519-3.CrossRefPubMed

121.

Chaudhary M, Sheikh N, Asterling S, Ahmad I, Greene D. Peyronie’s disease with erectile dysfunction: penile modeling over inflatable penile prostheses. Urology. 2005;65(4):760–4. https://doi.org/10.1016/j.urology.2004.10.039.CrossRefPubMed

122.

Montorsi F, Guazzoni G, Barbieri L, Maga T, Rigatti P, Graziottin A, et al. AMS 700 CX inflatable penile implants for Peyronie’s disease: functional results, morbidity and patient-partner satisfaction. Int J Impot Res. 1996;8(2):81–5 discussion 5-6.PubMed

123.

Austoni E, Colombo F, Romano AL, Guarneri A, Kartalas Goumas I, Cazzaniga A. Soft prosthesis implant and relaxing albugineal incision with saphenous grafting for surgical therapy of Peyronie’s disease: a 5-year experience and long-term follow-up on 145 operated patients. Eur Urol. 2005;47(2):223–9; discussion 9. https://doi.org/10.1016/j.eururo.2004.10.004.CrossRefPubMed

124.

Montague DK, Angermeier KW, Lakin MM, Ingleright BJ. AMS 3-piece inflatable penile prosthesis implantation in men with Peyronie’s disease: comparison of CX and Ultrex cylinders. J Urol. 1996;156(5):1633–5.CrossRef

125.

Usta MF, Bivalacqua TJ, Sanabria J, Koksal IT, Moparty K, Hellstrom WJ. Patient and partner satisfaction and long-term results after surgical treatment for Peyronie’s disease. Urology. 2003;62(1):105–9.CrossRef

Title: Management of the Acute Phase of Peyronie’s Disease: a Contemporary Review
Authors: Dyvon T. Walker
Arash Amighi
Steven A. Mills
Sriram V. Eleswarapu
Jesse N. Mills
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Erectile Dysfunction
Clostridium
Verapamil
Published in: Current Sexual Health Reports / Issue 4/2019
Print ISSN: 1548-3584
Electronic ISSN: 1548-3592
DOI: https://doi.org/10.1007/s11930-019-00220-z

At a glance: The STEP trials

Springer Medicine

Management of the Acute Phase of Peyronie’s Disease: a Contemporary Review

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2019

Interactions Between Inflammation and Female Sexual Desire and Arousal Function

The Medical Management of Gender Dysphoric, Gender Fluid, Gender Nonconforming, Gender Queer, Nonbinary, and Transgender Patients: One Clinic’s Approach

From Table to Bedroom: Nutritional Status, Dietary Interventions, and Women’s Sexual Function

Sexual Disgust: Evolutionary Perspectives and Relationship to Female Sexual Function

Sexuality and Intimacy Among Older Women Living with HIV: a Systematic Review

Female Sexual Dysfunction as a Warning Sign of Chronic Disease Development